News | News By Subject | News by Disease News By Date | Search News
Get Our FREE
Industry eNewsletter
email:    
   

3M Pharmaceuticals (MMM) And Takeda Pharmaceutical Co. Ltd. (TKDG.DE) To Collaborate On Potential Treatment For Cervical High-Risk HPV Infection And Cervical Dysplasia



10/19/2005 5:12:52 PM

ST. PAUL, Minn. & OSAKA, Japan--(BUSINESS WIRE)--March 1, 2005--3M and Takeda Pharmaceutical Company Limited (Takeda) announced today that the two companies entered into an exclusive co-development and joint marketing agreement to collaborate on a potential topical treatment for cervical high-risk human papillomavirus (HPV) infection and cervical dysplasia. The compound is currently in early stage (Phase I) clinical testing. Under the terms of this agreement, 3M and Takeda will share further costs of development. Upon successful clinical development and regulatory approvals, the companies will jointly commercialize in the United States and European Union. Takeda will retain exclusive rights in Japan and certain Asian countries, and 3M will have exclusive commercialization rights in all other areas of the world.

Read at BioSpace.com


comments powered by Disqus
   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES